Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

December 06, 2023 00:19:56
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3
COR2ED - Oncology Medical Conversation
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

Dec 06 2023 | 00:19:56

/

Show Notes

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

Other Episodes

Episode

April 25, 2024 00:32:21
Episode Cover

Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de...

Listen

Episode

December 06, 2023 00:30:42
Episode Cover

HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment...

Listen

Episode

April 25, 2024 00:29:54
Episode Cover

Cáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones...

Listen